ClinicalTrials.gg
CompletedNCT02096705Updated Aug 9, 2017Results posted

Phase III Insulin Add-On Asia Regional Program - ST

A Phase 3 interventional study of Dapagliflozin and Dapagliflozin Placebo in Diabetes, sponsored by AstraZeneca. Completed at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
477
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies testing dapagliflozin in Diabetes Mellitus — 8 open to participants now, 10 under way, 4 of them phase 3. dapagliflozin · Diabetes Mellitus.

Enrollment
11th of 51
477 · median 80
Started
2014
with 1 other
Phase 3
16 of 51
2 open now
Registered
12th of 51
by date
Lead sponsor
15 of 51
AstraZeneca

Among the 51 studies testing dapagliflozin in Diabetes Mellitus, this one is the 11th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 12th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

8 of the 51 studies testing dapagliflozin in Diabetes Mellitus are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing dapagliflozin in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects must have type 2 diabetes with inadequate glycemic control, defined as ≥ 7.5% and ≤ 11.0% obtained at screening visit
  • Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment

Inclusion criteria for randomization:

HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

Exclusion Criteria:

  • Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment
  • History of diabetic ketoacidosis of hyperosmolar nonketotic coma
  • Clinically diagnosed Type 1 diabetes mellitus
  • Congestive heart failure defined as (NYHA) stage III and IV
  • Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg
  • History of unstable or rapidly progressing renal disease
  • History of severe hepatobiliary disease
  • Mallingancy within 5 years of the screening/enrollment visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
477 participants (actual)

Study arms

  • Experimental
    Group 1: Dapagliflozin

    Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin

    Drug: Dapagliflozin

  • Placebo comparator
    Group 2: Dapagliflozin Placebo

    Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin

    Drug: Dapagliflozin Placebo

Interventions

  • Tablet

    Also known as: BMS-512148

  • DrugDapagliflozin Placebo

    Tablet

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change in HbA1c From Baseline to Week 24

    The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.

    Time frame: Baseline (Day 1) and 24 weeks

Secondary outcomes

  1. Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24

    The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).

    Time frame: Baseline (Day 1) and 24 weeks

  2. Adjusted Mean Change in Body Weight From Baseline to Week 24

    Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).

    Time frame: Baseline (Day 1) and 24 weeks

  3. Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24

    The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).

    Time frame: Baseline (Day 1) and 24 weeks

07

Results

Posted Mar 6, 2017

Participant flow

Treatment
Participant flow — Treatment
MilestonePlaceboDapagliflozin
Started133139
Completed124134
Not completed95
Withdrew: Adverse event63
Withdrew: Subject request to discontinue treatment11
Withdrew: Withdrawal by subject10
Withdrew: Other11
Follow-up
Participant flow — Follow-up
MilestonePlaceboDapagliflozin
Started129139
Completed125135
Not completed44
Withdrew: Withdrawal by subject10
Withdrew: Adverse event22
Withdrew: Subjects not reporting status12

Outcome measures

PrimaryAdjusted Mean Change in HbA1c From Baseline to Week 24

The adjusted mean change in the percentage of Hemoglobin A1c (HbA1c) from baseline to Week 24 was reported for each arm.

Time frame:
Baseline (Day 1) and 24 weeks
Reported as:
Mean · percentage of hemoglobin
Adjusted Mean Change in HbA1c From Baseline to Week 24
percentage of hemoglobinPlaceboDapagliflozin
Adjusted Mean Change in HbA1c From Baseline to Week 240.03 ± 0.0707-0.87 ± 0.0666
Statistical analysis
  • Placebo vs Dapagliflozin · Longitudinal repeated measure analysis · p = <0.0001 (P-value for Dapagliflozin vs. placebo) · Mean difference (final values): -0.90 · 95% CI -1.09 to -0.71Difference of Dapagliflozin from placebo
SecondaryAdjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24

The adjusted mean change from baseline to 24 weeks in Fasting Plasma Glucose (FPG) was reported for each arm in milligrams per deciliter (mg/dL).

Time frame:
Baseline (Day 1) and 24 weeks
Reported as:
Mean · mg/dL
Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24
mg/dLPlaceboDapagliflozin
Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 240.07 ± 3.3803-30.62 ± 3.1314
Statistical analysis
  • Placebo vs Dapagliflozin · Longitudinal repeated measure analysis · p = <0.0001 · Mean difference (final values): -30.69 · 95% CI -39.76 to -21.61Difference of Dapagliflozin from placebo
SecondaryAdjusted Mean Change in Body Weight From Baseline to Week 24

Adjusted mean change in body weight from baseline to week 24 was reported for each arm in kilograms (kg).

Time frame:
Baseline (Day 1) and 24 weeks
Reported as:
Mean · kilograms
Adjusted Mean Change in Body Weight From Baseline to Week 24
kilogramsPlaceboDapagliflozin
Adjusted Mean Change in Body Weight From Baseline to Week 240.37 ± 0.2224-1.00 ± 0.2103
Statistical analysis
  • Placebo vs Dapagliflozin · Longitudinal repeated measure analysis · p = <0.0001 (P-value for Dapagliflozin vs. placebo) · Mean difference (final values): -1.38 · 95% CI -1.98 to -0.77Difference of Dapagliflozin from placebo
SecondaryAdjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24

The adjusted mean change in absolute calculated mean Total Daily Dose of Insulin (TDDI) from baseline to week 24 was reported for each arm in International Units (IU).

Time frame:
Baseline (Day 1) and 24 weeks
Reported as:
Mean · International Units (IU)
Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24
International Units (IU)PlaceboDapagliflozin
Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 240.74 ± 0.3723-0.70 ± 0.3592
Statistical analysis
  • Placebo vs Dapagliflozin · Longitudinal repeated measure analysis · p = 0.0059 (P-value for Dapagliflozin vs. placebo) · Mean difference (final values): -1.43 · 95% CI -2.45 to -0.42Difference of Dapagliflozin from placebo

Adverse events

Collected over 24 week treatment period + 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin—8/139 (5.8%)61/139 (43.9%)
Placebo—18/133 (13.5%)61/133 (45.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventDapagliflozinPlacebo
FOOT DEFORMITYMusculoskeletal and connective tissue disorders0/1392/133
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/1391/133
ANGINA PECTORISCardiac disorders0/1391/133
MYOCARDIAL BRIDGINGCongenital, familial and genetic disorders0/1391/133
CATARACTEye disorders0/1391/133
UVEITISEye disorders0/1391/133
NEUROSYPHILISInfections and infestations0/1391/133
HUMERUS FRACTUREInjury, poisoning and procedural complications0/1391/133
HYPERGLYCAEMIAMetabolism and nutrition disorders0/1391/133
PERIARTHRITISMusculoskeletal and connective tissue disorders0/1391/133
Most frequent other events
Most frequent other events
EventDapagliflozinPlacebo
HYPERLIPIDAEMIAMetabolism and nutrition disorders31/13931/133
DYSLIPIDAEMIAMetabolism and nutrition disorders9/13912/133
HYPERURICAEMIAMetabolism and nutrition disorders12/13912/133
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/1399/133
NASOPHARYNGITISInfections and infestations5/1397/133
URINARY TRACT INFECTIONInfections and infestations5/1397/133

Baseline characteristics

All Randomized Participants

Age, Categorical
Age, Categorical(Participants)PlaceboDapagliflozinTotal
<=18 years000
Between 18 and 65 years97117214
>=65 years362258
Age, Continuous
Age, Continuous(years)PlaceboDapagliflozinTotal
Mean58.6 ± 8.9156.5 ± 8.3957.5 ± 8.70
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDapagliflozinTotal
Female6973142
Male6466130
08

Study locations

29 sites
  • Local Institution
    Beijing, Beijing 100029, China
  • Local Institution
    Beijing, Beijing 100700, China
  • Local Institution
    Beijing, Beijing 100730, China
  • Local Institution
    Guangzhou, Guangdong 510080, China
  • Local Institution
    Guangzhou, Guangdong 510120, China
  • Local Institution
    Haerbin, Heilongjiang 150001, China
  • Local Institution
    Changsha, Hunan 410000, China
  • Local Institution
    Changsha, Hunan 410008, China
  • Local Institution
    Nanjing, Jiangsu 210012, China
  • Local Institution
    Suzhou, Jiangsu 215004, China
  • Local Institution
    Wuxi, Jiangsu 214023, China
  • Local Institution
    Changchun, Jilin 130041, China
  • Local Institution
    Shanghai, Shanghai 200040, China
  • Local Institution
    Shanghai, Shanghai 200072, China
  • Local Institution
    Shanghai, Shanghai 200080, China
  • Local Institution
    Shanghai, Shanghai 200092, China
  • Local Institution
    Xi An, Shanxi 710032, China
  • Local Institution
    Xi'an, Shanxi 710061, China
  • Local Institution
    Chengdu, Sichuan 610072, China
  • Local Institution
    Chongqing, Sichuan 400010, China
  • Local Institution
    Beijing, 100039, China
  • Local Institution
    Tianjin, China
  • Local Institution
    Busan, 49241, Korea, Republic of
  • Local Institution
    Daegu, 42415, Korea, Republic of
  • Local Institution
    Daejeon, 35233, Korea, Republic of
  • Local Institution
    Seoul, 06351, Korea, Republic of
  • Local Institution
    Seoul, 134-727, Korea, Republic of
  • Local Institution
    Singapore, 169856, Singapore
  • Local Institution
    Singapore, 529889, Singapore
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jan 2016, 21 months.

Results were first posted in Mar 2017, 1 year 1 month after primary completion.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 21 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2014
First posted
Mar 26, 2014
StartActual
Mar 31, 2014
Primary completionActual
Jan 28, 2016
CompletionActual
Jan 28, 2016
Results first posted
Mar 6, 2017
Last update
Aug 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02096705
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 26, 2014
Start date
Mar 31, 2014
Primary completion
Jan 28, 2016
Completion
Jan 28, 2016
Results posted
Mar 6, 2017
Last update
Aug 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion